Finch A, Solomou G, Wykes V, Pohl U, Bardella C*, Watts C.* (*joint last authors). Advances in Research of Adult Gliomas. Int J Mol Sci. 2021Jan18;22(2):924.doi:10.3390/ijms22020924.PMID: 33477674 Review.
Walsby-Tickle J, Gannon J, Hvinden I, Bardella C, Abboud MI, Nazeer A, Hauton D, Pires E, Cadoux-Hudson T, Schofield CJ, McCullagh JSO. Anion-exchange chromatography mass spectrometry provides extensive coverage of primary metabolic pathways revealing altered metabolism in IDH1 mutant cells. Commun Biol. 2020 May 20;3(1):247. doi: 10.1038/s42003-020-09576.PMID: 32433536.
Lee LY, Woolley CE, Starkey T, Biswas S, Mirshahi TS, Bardella C, Segditsas S, Irshad S, Tomlinson I. Serum- and glucocorticoid-induced kinase sgk1 directly promotes the differentiation of colorectal cancer cells and restrains metastasis. Clin Cancer Res. 2018 Oct 15. pii: clincanres.1033.2018. doi: 10.1158/1078-0432.CCR-18-1033.
Bardella C*, Al-Shammari AR*, Soares L*, Tomlinson I, O'Neill E and Szele FG (*joint first authors). The Role of Inflammation in Subventricular Zone Cancer. Prog Neurobiol. 2018 Apr 11. pii: S0301-0082(17)30198-3. doi: 10.1016/j.pneurobio.2018.04.007. Review.
Hollinshead KER, Munford H, Eales K, Bardella C, Li C, Escribano-Gonzalez C, Thakker A, Nonnenmacher Y, Kluckova K, Jeeves M, Murren R, Cuozzo F, Ye D, Laurenti G, Zhu W, Hiller K, Hodson DJ, Hua W, Tomlinson I, Ludwig C, Mao Y, Tennant DA. Oncogenic IDH1 mutations promote enhanced proline synthesis through PYCR1 to support the maintenance of mitochondrial redox homeostasis. Cell Rep. 2018 Mar 20;22(12):3107-3114. doi: 10.1016/j.celrep.2018.02.084.
Irshad S, Bansal M, Guarnieri P, Davis H, Zen A, Biswas S, Pinna M, Bardella C, Jeffery R, Wang LM, East JE, Tomlinson I, Leedham SJ. Bone Morphogenetic Protein and Notch signaling crosstalk in poor prognosis, mesenchymal subtype colorectal cancer. J Pathol. 2017 Mar 15. doi: 10.1002/path.4891.
Bardella C, Al-Dalahmah O, Krell D, Brazauskas P, Al-Qahtani K, Tomkova M, Adam J, Serres S, Lockstone H, Freeman-Mills L, Pfeffer I, Sibson N, Goldin R, Schuster-Böeckler B, Pollard PJ, Soga T, McCullagh JS, Schofield CJ, Mulholland P, Ansorge O, Kriaucionis S, Ratcliffe PJ, Szele FG and Tomlinson I. Expression of Idh1R132H in the murine subventricular zone stem cell niche recapitulates features of early gliomagenesis. Cancer Cell. 2016 Sep 21. pii: S1535-6108(16)30402-0. doi: 10.1016/j.ccell.2016.08.017; (front cover).
Kovac M*, Navas C*, Horswell S*, Salm M*, Bardella C*, Rowan A, Stares M, Castro-Giner F, Fisher R, de Bruin EC, Kovacova M, Gorman M, Makino S, Williams J, Jaeger E, Jones A, Howarth K, Larkin J, Pickering L, Gore M, Nicol DL, Hazell S, Stamp G, O'Brien T, Challacombe B, Matthews N, Phillimore B, Begum S, Rabinowitz A, Varela I, Chandra A, Horsfield C, Polson A, Tran M, Bhatt R, Terracciano L, Eppenberger-Castori S, Protheroe A, Maher E, El Bahrawy M, Fleming S, Ratcliffe P, Heinimann K, Swanton C, Tomlinson I. (*joint first authors). Recurrent chromosomal gains and heterogeneous driver mutations characterise papillary renal cancer evolution. Nat Commun. 2015 Mar 19;6:6336. doi: 10.1038/ncomms7336.
Krell D, Mulholland P, Stebbing J, Tomlinson I, Bardella C. HOT mutation screening in human glioblastomas. Future Sci OA. 2015;1(3). pii: FSO22.
Davis H, Irshad S, Bansal M, Rafferty H, Boitsova T, Bardella C, Jaeger E, Lewis A, Freeman-Mills L, Giner FC, Rodenas-Cuadrado P, Mallappa S, Clark S, Thomas H, Jeffery R, Poulsom R, Rodriguez-Justo M, Novelli M, Chetty R, Silver A, Sansom OJ, Greten FR, Wang LM, East JE, Tomlinson I, Leedham SJ. Aberrant epithelial GREM1 expression initiates colonic tumorigenesis from cells outside the stem cell niche. Nat Med. 2015 Jan;21(1):62-70. doi: 10.1038/nm.3750.
Krell D, Mulholland P, Frampton AE, Krell J, Stebbing J, Bardella C. IDH mutations in tumorigenesis and their potential role as novel therapeutic targets. Future Oncol. 2013 Dec;9(12):1923-35. doi: 10.2217/fon.13.143. Review.
Bardella C, Olivero M, Lorenzato A, Geuna M, Adam J, O'Flaherty L, Rustin P, Tomlinson I, Pollard PJ, Di Renzo MF. Cells lacking the fumarase tumor suppressor are protected from apoptosis through a hypoxia-inducible factor-independent, AMPK-dependent mechanism. Mol Cell Biol. 2012 Aug;32(15):3081-94. doi: 10.1128/MCB.06160-11.
Schödel J, Bardella C, Sciesielski LK, Brown JM, Pugh CW, Buckle V, Tomlinson IP, Ratcliffe PJ, Mole DR. Common genetic variants at the 11q13.3 renal cancer susceptibility locus influence binding of HIF to an enhancer of cyclin D1 expression. Nat Genet. 2012 Mar 11;44(4):420-5, S1-2. doi: 10.1038/ng.2204.
Bardella C, Pollard PJ, Tomlinson I. SDH mutations in cancer. Biochim Biophys Acta. 2011 Nov;1807(11):1432-43. doi:10.1016/j.bbabio.2011.07.003. Review.
Bardella C, El-Bahrawy M, Frizzell N, Adam J, Ternette N, Hatipoglu E, Howarth K, O'Flaherty L, Roberts I, Turner G, Taylor J, Giaslakiotis K, Macaulay VM, Harris AL, Chandra A, Lehtonen HJ, Launonen V, Aaltonen LA, Pugh CW, Mihai R, Trudgian D, Kessler B, Baynes JW, Ratcliffe PJ, Tomlinson IP, Pollard PJ. Aberrant succination of proteins in fumarate hydratase-deficient mice and HLRCC patients is a robust biomarker of mutation status. J Pathol. 2011 May 10. doi: 10.1002/path.2932; (front cover).
Krell D, Assoku M, Galloway M, Mulholland P, Tomlinson I, Bardella C. Screen for IDH1, IDH2, IDH3, D2HGDH and L2HGDH Mutations in Glioblastoma. PLoS One. 2011;6(5):e19868. doi: 10.1371/journal.pone.0019868.
Ashrafian H, O'Flaherty L, Adam J, Steeples V, Chung YL, East P, Vanharanta S, Lehtonen H, Nye E, Hatipoglu E, Miranda M, Howarth K, Shukla D, Troy H, Griffiths J, Spencer-Dene B, Yusuf M, Volpi E, Maxwell PH, Stamp G, Poulsom R, Pugh CW, Costa B, Bardella C, Di Renzo MF, Kotlikoff MI, Launonen V, Aaltonen L, El-Bahrawy M, Tomlinson I, Pollard PJ. Expression profiling in progressive stages of fumarate-hydratase deficiency: the contribution of metabolic changes to tumorigenesis. Cancer Res. 2010 Nov 15;70(22):9153-65. doi: 10.1158/0008-5472.CAN-10-1949.
Costa B, Dettori D, Lorenzato A, Bardella C, Coltella N, Martino C, Cammarata C, Carmeliet P, Olivero M, Di Renzo MF. Fumarase tumor suppressor gene and MET oncogene cooperate in upholding transformation and tumorigenesis. FASEB J. 2010 Aug;24(8):2680-8. doi: 10.1096/fj.09-146928.
Cardamone MD, Bardella C, Gutierrez A, Croce LD, Rosenfeld MG, Di Renzo MF, De Bortoli M. ER{alpha} as ligand-independent activator of CDH-1 regulates determination and maintenance of epithelial morphology in breast cancer cells. Proc Natl Acad Sci U S A. 2009 May 5;106(18):7420-5. doi: 10.1073/pnas.0903033106.
Bardella C, Dettori D, Olivero M, Coltella N, Mazzone M and Di Renzo MF. The therapeutic potential of Hepatocyte Growth Factor to sensitize ovarian cancer cells to cisplatin and paclitaxel in vivo. Clin Cancer Res,13 (7): 2191-8, April 1, 2007.
Coltella N, Rasola A, Nano E, Bardella C, Fassetta M, Filigheddu N, Graziani A, Comoglio PM, Di Renzo MF. p38 MAPK turns hepatocyte growth factor to a death signal that commits ovarian cancer cells to chemotherapy-induced apoptosis. Int J Cancer, 118 (12): 2981-90, June 15, 2006.
Bardella C, Costa B, Maggiora P, Patanè S, Olivero M, Ranzani N, De Bortoli M, Comoglio PM, Di Renzo MF. Truncated RON tyrosine kinase drives tumor cell progression and abrogates cell-cell adhesion through E-cadherin transcriptional repression. Cancer Res, 64: 5154-5161, August 1, 2004.
View all publications in research portal